ClinicalTrials.Veeva

Menu
P

Piedmont Eye Center Inc | Lynchburg, VA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
Ranibizumab
JNJ-81201887
Netarsudil
Latanoprost
PG043
Tarcocimab
Vamikibart
RO7200220
Bimatoprost

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 13 total trials

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibo...

Enrolling
Dry Eye Disease
Other: Vehicle
Drug: AZR-MD-001

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with modera...

Active, not recruiting
Dry Eye Disease
Drug: TL-925
Other: Placebo

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Drug: Vamikibart

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects...

Begins enrollment in 1 month
Open Angle Glaucoma
Ocular Hypertension
Drug: AR-17043 Ophthalmic Solution
Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

A study of the Streamline Surgical System versus competitor

Enrolling
Open Angle Glaucoma
Device: Streamline Surgical System
Device: iStent Inject W

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Enrolling
Macular Degeneration
Drug: Ranibizumab
Drug: Zifibancimig

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Intravitreal Ranibizumab 0.5 mg Injection

Trial sponsors

Roche logo
AbbVie logo
Alcon logo
A
Genentech logo
Janssen (J&J Innovative Medicine) logo
Kodiak Sciences logo
M
N
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems